

**Gynecologic Cancer InterGroup
Cervix Cancer Research Network**



QA for Cervix Cancer Trials in Asia

Sang Young Ryu, MD
Dept. Gynecologic Oncology
Korea Cancer Center Hospital

Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand



- **What is Quality Assurance (QA)?**
 - Independent examination of all trial-related activities and documents.
 - Activities were appropriately conducted
 - Data were generated, recorded, analyzed, and accurately reported according to protocol, standard operating procedures (SOPs), and good clinical practices (GCPs).



- **What is Good Clinical Practice (GCP)?**
 - *“a set of internationally recognized ethical and scientific quality requirements”*
 - *“for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects.”*



Components for QA

- Standard operating procedures (SOPs) for trial execution
- A quality scientific and medical design of the protocol
- Clinical investigator and site pre-assessment and selection
- Regulatory agency and ethics committee approval
- Developing and providing appropriate informed consent
- Investigator meetings and training
- Adequate recording and reporting of data
- Periodic monitoring
- Audits

Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand



- **Components of data management (DM)**
 - Case report form [CRF] vs. protocol
 - CRF vs. source documents
 - Database vs. CRF
 - Tables, listings, and graphs (TLGs) vs. database
 - Data reported in the clinical study report (CSR) vs. TLGs
 - All are compliant with SOPs and GCPs



Benefit of QA

- QA promotes;
 - Confidence
 - Improves communication
 - Understanding of community needs and expectations
 - Increasing their job satisfaction and status in the community
 - Provides tools that gauge current performance levels and facilitate continuous improvement



Clinical Trial in Developing Countries

- Risk of **exploitation**:
 - Developing countries take the risks
 - But most of the benefits to developed countries
- Poverty, limited health-care services, illiteracy, cultural and linguistic differences, and limited understanding of the nature of scientific research



Clinical Trial in Developing Countries

- Collaborative partnership (Emanuel et al., 2004)
 - Partners representing developing country
 - Collaboration; sharing responsibility
 - Mutual respect
 - Minimize disparities
 - Fair benefits
 - Fair distribution of rewards of research



Cervical Cancer Research Network (CCRN)

- To promote high quality clinical research
 - Pre-visit questionnaire
 - Site visit
 - Beam measurement program (TLD/OSLD)
 - Data input to IROC
 - Trial specific RT QA



Basic Requirements for EBRT

- OSLD/TLD every two years
- Credentialing procedures that include tabular data on department infrastructure (personnel, machines, beam profile data, etc...)
- Port films obtained \geq weekly
- Physician visits documented weekly for trial patients
- Treatment plan signed by Radiation Oncologist prior to treatment
- Protocol specific knowledge assessment
- All fields must be filmed (simulation preferred).
- 2D therapy is permissible as well as Cobalt teletherapy. Central axis dosimetry is recommended (not mandatory for the lowest resource settings).



Basic Requirements for Brachytherapy

- Description of prescription volume or point
- Dose calculation signed by physicist and physician prior to treatment.
- Source activity documentation
- Brachytherapy questionnaire of resources: activity traceable to standard, dose calculation method



- **Clinical Management: Basic Requirements**

- Charts must contain: Pathology report, stage, and consent
- Clinical follow up \leq every 6 months for two years, and then less often per trial.
- In low resource trials, phone call documentation of vital status by an eye witness is acceptable.
- Documentation of GCP recommended
- Data Management process
 - Ability to complete CRFs
 - ethics submissions,
 - following schedules (investigations, etc), monitoring,
 - adequate [locked] pharmacy facilities,
 - Assuring FU capabilities




INTERLACE; UK

OUTBACK: GOG

SHAPE: Canada

TACO: Korea/Thailand

Gynecologic Cancer InterGroup Cervix Cancer Research Network




Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand



Innovation is not a creation out of nothing, but
a new combination of things already known.

Gynecologic Cancer InterGroup Cervix Cancer Research Network





RT QA in TACO

- Pretreatment AP/Lat portal film review
 - within 24 hours
- Post treatment RT review
 - William Small, Chomporn Sitatane, HackJae Kim
 - Biennial meeting
 - Acceptable/Deviation acceptable/Unacceptable

Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand

RT-QA

(1st RT-Film review 2012. 11)

(2nd RT-Film review at Bangkok 2013.4)



Gynecologic Cancer InterGroup Cervix Cancer Research Network



RT QA in TACO




Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand


Gynecologic Cancer InterGroup Cervix Cancer Research Network



Deviation




Deviation



- Major
- Minor
- Per

Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand

RT QA in TACO




Gynecologic Cancer InterGroup Cervix Cancer Research Network




1 st QC Deviation	2 nd QC Deviation
17%	7%

1st QC Monitoring



2nd QC Monitoring



Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand



Summary

QA in Clinical Trial

- Data were generated, recorded, analyzed, and accurately reported
- By protocol, SOPs, and GCPs

QA promotes

- Confidence
- Gauge current performance levels and improvement

Thank you for your attention.

Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand